Industry News

Cara Therapeutics Inc, Zynerba Pharmaceuticals Inc., Terra Tech Corp., GW Pharmaceuticals PLC."/>
The Growth of the Legal and Medical Marijuana Markets
OrganiGram Holdings Inc. is pleased to announce that it has closed its previously announced short form prospectus offering, on a bought deal basis, including the full exercise of the over-allotment option. As such, a total of 17,710,000 common shares of the Company were sold at a price of $1.30 per Share, for aggregate gross proceeds of $23,023,000. The Offering was completed by a syndicate of underwriters led by Dundee Securities Ltd., and..."/>
OrganiGram Announces Closing of $23M Bought Deal Financing
Propanc Health Group Corporation, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced it has executed a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium. The agreement covers the development and GMP production of certain enzymes for development purposes,..."/>
Propanc Enters Into Contract Manufacturing Agreement With AmatsiQBiologicals
Decision Diagnostics Corp., the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate! ™glucose test strips, both designed to work with the market leading Johnson& Johnson's LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure! ™glucose test strips targeted to the U.S. and/or developing world markets today conveys..."/>
DECN Litigation Victory Against Johnson + Johnson, Launches Foothold in On-Line Retail Markets for Its Popular "Gen" Products
SpectraScience, Inc., a medical device company utilizing light technologies to detect and diagnose cancers, announced today that Professor Venkat Subramanian presented his findings of the WavSTAT Optical Biopsy System ® to the British Society of Gastroenterology on June 23rd. The clinical trials were performed at St. Subramanian concluded that once again WavSTAT was found to exceed the clinical guidelines adopted by EU and US medical societies for..."/>
SpectraScience Announces Accuracy of WavSTAT4 in the Diagnosis of Small Colorectal Cancer Polyps Confirmed
Perrigo Company plc today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Suprep ® oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults."/>
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep® Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso® Gel
CEL-SCI Corporation today announced it has entered into a definitive agreement with institutional investors to purchase approximately 10 million shares of its common stock and warrants exercisable for up to approximately 5 million shares of its common stock for gross proceeds of $5 million. The warrants will be exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date and have an exercise price of..."/>
CEL-SCI Announces $5 Million Registered Direct Offering
Triple-S Management Corporation today announced that Roberto García-Rodríguez, Chief Executive Officer, and Juan José Román-Jiménez, Chief Financial Officer, will present to investors and financial analysts at the Wells Fargo Securities Research, Economics and Strategy 2016 Health Care Conference in Boston, MA on Wednesday, September 7. The fireside chat will be broadcast live through the Internet at 4:05 p.m. Eastern..."/>
Triple-S Management Corporation to Present at the Wells Fargo Securities 2016 Healthcare Conference
Brainsway ® USA Inc., a subsidiary of Brainsway Ltd., a leader in the advanced non-invasive treatment of brain disorders, announces the promising results of its consolidated financial reports for Q2 2016 and provides company updates. The report shows a total revenue..."/>
Brainsway Reports Consistent Revenue Growth for Third Quarter in a Row and Provides Company Updates
Meridian Bioscience, Inc. today announced the launch of their Analyte Specific Reagent product line. The first ASR products include a primer set and probes for detection of Helicobacter pylori and the target sequence associated with Clarithromycin-resistant H. pylori strains.. Richard L. Eberly, President, Chief Commercial Officer stated,“ As a consistent innovator and market share leader for in vitro diagnostic devices, it is important that Meridian’ s..."/>
Meridian Bioscience Expands Its Portfolio and Launches First Analyte Specific Reagent (ASR) Products
Sophiris Bio Inc., a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced the pricing of an underwritten public offering of 6,500,000 of its common shares and related warrants to purchase 4,875,000 of its common shares with an exercise price of $4.00 per share, offered at a combined price to the public of $4.00 per share and related warrant."/>
Sophiris Bio Prices Public Offering of Common Shares and Warrants
Gilead Sciences, Inc. announced today that Kelly A. Kramer has been appointed to the company’ s Board of Directors and Audit Committee. Kramer is currently Executive Vice President and Chief Financial Officer of Cisco Systems, Inc., which designs and sells products, services and solutions to securely connect everyone and everything. She previously served for 20 years in senior finance positions at General Electric, including as Chief Financial Officer of..."/>
Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
WellCare Health Plans, Inc. announced today it has appointed Rhonda Mims to the newly created position of senior vice president and chief public affairs officer, effective Aug. 23. Mims will be responsible for the development and implementation of the company's strategic communications, public policy, corporate social responsibility, philanthropy, diversity and inclusion, and employee volunteerism. Mims will report to WellCare's CEO Ken..."/>
WellCare Appoints Rhonda Mims Chief Public Affairs Officer
Laboratory Corporation of America ® Holdings today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc. by LabCorp has expired. As previously announced, LabCorp and Savoy Acquisition Corp., its direct wholly owned subsidiary, commenced a tender offer on August 9, 2016, for all of the outstanding shares of common stock of Sequenom, including the..."/>
LabCorp’s Acquisition of Sequenom Clears Antitrust Review
WellCare Health Plans, Inc. announced that effective Oct. 1, 2016, Larry Anderson, senior vice president and chief human resources officer, is leaving the company. Effective Aug. 22, 2016, Anderson is no longer an executive officer, but will remain with WellCare after this time to assist with the transition of his duties and responsibilities. "Larry made significant contributions during his nearly six years with WellCare, including helping to..."/>
WellCare Announces Departure of Chief Human Resources Officer
Tiger X Medical, Inc.. The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia. The combined entity is expected to have $23 million in cash at..."/>
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure
Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced the official opening of its U.S. headquarters in Boston, Massachusetts. The new office space is located at 127 Main Street, in close proximity to the plethora of life science companies and teaching hospitals in the area. "I am thrilled to be heading up our Boston office and..."/>
Critical Outcome Technologies Announces the Opening of Its U.S. Headquarters
Trimedyne, Inc. today reported its financial results for the quarter and nine-month period ended June 30, 2016.. Revenues for the current quarter were $1,106,000, a decrease of 25% from revenues of $1,482,000 for the prior year's quarter. The decrease in revenues was primarily due to a decrease in sales of Lasers and accessories compared to the prior year period."/>
Trimedyne Reports Its Financial Results for the Quarter and Nine Months Ended June 30, 2016
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia at the American Society for Bone and Mineral Research 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.. Two oral presentations will..."/>
Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting
BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has entered into a strategic partnership with Bloom Technologies, Inc., an early stage digital health company. Under the terms of the agreement, Bloomlife will pay BioTelemetry a percentage of revenue to license their proprietary telemetry technology to..."/>
BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market
Oragenics, a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation lantibiotic, OG716, for treatment of Clostridium difficile and plans to begin Investigational New Drug enabling studies. OG716, a new, orally-active homolog, has exhibited positive results in an animal model for potential treatment of Clostridium difficile."/>
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, has again partnered with Integrated Medical Foundation and LUGPA, an association of independent urology group practices, to raise awareness of prostate cancer amid new evidence about the importance of early detection. In recognition of September as National Prostate Cancer Awareness..."/>
Henry Schein Joins IMF and LUGPA to Raise Awareness of Prostate Cancer and the Importance of Early Detection

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary511 Articles
Information Technology471 Articles
Financials413 Articles
Industrials305 Articles
Health Care270 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.